Bulls Keep Del Fris...
Health Care: Drugs
StemCells Inc. (STEM: NASDAQ)
$1.93 0.06 | 3.21%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -28.49M | -21.33M | -25.24M | -27.03M |
| Operating Gains/Losses | 20.88K | -51.60K | -169.89K | -406.91K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -10.63K | -10.53K | 511.14K | 275.73K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -409.33K | 130.77K | -808.72K | 477.17K |
| (Decrease) Increase In Other Current Liabilities | -1.03M | -1.17M | -1.20M | -1.03M |
| (Increase) Decrease In Other Working Capital | 188.75K | 1.36M | 322.78K | -1.10M |
| Other Non-Cash Items | 8.85M | -2.70M | 987.40K | 2.30M |
| Net Cash From Continuing Operations | -19.87M | -22.06M | -24.52M | -24.68M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -19.87M | -22.06M | -24.52M | -24.68M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 5.76M | 7.06M | 0.00 | 9.51M |
| Purchases of Property, Plant & Equipment | -73.08K | -296.93K | -923.96K | -716.24K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -16.38M | -10.19M | 0.00 | -4.98M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | -79.83K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -10.69M | -3.42M | -923.96K | 3.73M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 128.56K |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 25.95M | 19.37M | 7.30M | 30.19M |
| Repayment of Long-Term Debt | -211.42K | -244.10K | -229.25K | -149.17K |
| Repurchase of Capital Stock | 0.00 | 0.00 | -483.41K | -380.55K |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 25.74M | 19.13M | 6.59M | 29.79M |
| Effect of Exchange Rate Changes | -15.92K | -45.75K | -52.66K | -260.61K |
| Net Change in Cash & Cash Equivalents | -4.84M | -6.40M | -18.91M | 8.57M |
Portfolios with STEM
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- User8 Stocks Under $10 Making B...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserStocks
- Contributor5 Biggest Drug-Stock Losers...
Latest STEM Headlines from TheStreet
- StemCells, Inc. Adds Byers Eye Institute At Stanford As Second Site For Phase I/II Clinical Trial In Dry Age-Related Macular Degeneration 04.18.13 | 09:04 am
- StemCells, Inc. To Participate At 2013 Regen Med Investor Day In New York 04.15.13 | 09:04 am
- StemCells, Inc. Enters Agreement To Receive $19.3 Million From California Institute For Regenerative Medicine To Help Fund IND For Alzheimer's Disease 04.11.13 | 09:04 am
- CORRECTION -- StemCells, Inc. Closes $10 Million Debt Financing 04.09.13 | 04:04 pm
- StemCells, Inc. Closes $10 Million Debt Financing 04.09.13 | 09:04 am
- StemCells, Inc. Expands Patent Portfolio 03.20.13 | 09:03 am
- StemCells, Inc. Reports Fourth Quarter And Full Year 2012 Financial Results And Provides Business Update 03.19.13 | 09:03 am
- 4 Biotech Stocks Under $5 to Watch 03.15.13 | 07:03 am
- Stocks Mixed; Dow Reclaims 14,000 02.12.13 | 02:02 pm
- StemCells, Inc. Announces First Patient Cohort Completes Spinal Cord Injury Trial - Gains In Sensory Function Persist 12 Months After Stem Cell Transplant 02.12.13 | 07:02 am
Press Releases for STEM
- Over $400 Million Raised By U.S. Life Sciences Companies Through At-the-Market (ATM) Offerings In 2012, Reports Brinson Patrick - PR Newswire 04.08.13 | 08:04 am
Partner Headlines for STEM
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- StemCells Partners With R Biomedical - Benzinga 10.30.12 | 09:10 am
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- StemCells Says Achieved First Neural Stem Cell Transplant Into Patient With Sensory Function Below the Level of Injury - Benzinga 09.27.12 | 09:09 am
- Why the bear market is finally ending - NASDAQ 09.13.12 | 01:09 pm
- Today's Market News To Trade On: 5 Stocks Moving On News - Seeking Alpha 08.31.12 | 08:08 am
- Nexen ENTERS Into Agreement With CNOOC and 4 Hot Stocks On the Move - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- One Stock To Buy, Two Avoids, And A Swing Trade From Last Week's Big Biotech News Movers - Seeking Alpha 07.21.12 | 06:07 am
- Healthcare Stock Insights: Vivus Wins FDA Diet Drug THUMBS UP, StemCells Give BACK - Wall St. Cheat Sheet 07.19.12 | 08:07 am
